T he majority of significant human and animal pathogenic viruses have RNA genomes. Influenza, measles, mumps, rubella, polio, rabies, yellow fever, dengue, and Ebola hemorrhagic fever are among the better known human examples. However, for the field of oncolytic virotherapy, RNA viruses present a vast and largely untapped resource. RNA virus genomes range in size from 7 to 30 kb and may be single -stranded ( positive or negative polarity ) or double -stranded, nonsegmented or segmented, with genome replication taking place in the cytoplasm or nucleus. At the time of writing this review, the most promising oncolytic RNA viruses are attenuated strains of mumps virus, Newcastle disease virus ( NDV ), measles virus, vesicular stomatitis virus, human reovirus, poliovirus, and influenza virus.
The most important characteristic of an oncolytic virus is that it propagates more efficiently in tumors than in normal host tissues. For oncolytic DNA viruses, this tumor specificity is often determined at the transcriptional level and is ultimately dependent on the interactions between nuclear transcription factors and viral promoter / enhancer elements. Obviously, RNA viruses are not subject to the influence of nuclear transcription factors, and must rely on an alternative mechanistic basis for their preferential replication in tumor cells. Integral to the life cycles of all RNA viruses is the formation of double -stranded RNA, a potent stimulator of PKR, a protein kinase that inhibits protein synthesis and promotes apoptosis, thereby controlling the spread of the virus infection. Another action of double -stranded RNA is to stimulate release of interferons, which activate PKR in adjacent uninfected cells, thereby protecting them from virus infection. Tumors are frequently defective in their PKR signaling pathway, and therefore provide a relatively permissive substrate for the propagation of RNA viruses. RNA virus specificity for tumor cells may also be a consequence of specific receptor usage for virus entry or for cell -to -cell fusion or, alternatively, may be due to the specific activity of a viral internal ribosome entry site.
For most of the oncolytic RNA viruses discussed in this review, tumor specificity is either a natural characteristic of the virus, or a serendipitous consequence of adapting the virus to propagate in human tumor cell lines. However, further refinement and optimization of oncolytic potency, specificity, and therapeutic utility can be achieved through virus engineering. ''Reverse genetics'' systems for the rescue of positive -strand RNA viruses ( e.g., poliovirus) from complementary DNA are relatively simple because infectious viruses can be generated from mRNA. In contrast, rescue systems from negative -strand RNA viruses ( e.g., measles virus, influenza virus ) are highly complex and have only recently become available because the minimal infectious unit for these viruses is the ribonucleoprotein polymerase complex. For segmented double -stranded RNA viruses (e.g., reovirus ), the problems are even more formidable, and convenient strategies for virus engineering do not yet exist. In general, there are three approaches to the engineering of RNA viruses that have been adopted in order to enhance their utility as oncolytic agents. First is to engineer the viral envelope or capsid proteins in an attempt to redirect virus entry through receptors expressed at high levels on the tumor cell surface. The second is to disable viral genes whose encoded proteins counter the cellular responses to double -stranded RNA and to interferon. The third engineering strategy is to add into the viral genome additional cistrons coding either for proteins that facilitate virus tracking or proteins that enhance the potential for killing of uninfected bystander tumor cells. In the remainder of this article, we review the current status of oncolytic virotherapy efforts for seven different RNA viruses, namely, mumps, NDV, measles virus, vesicular stomatitis virus, influenza, reovirus, and poliovirus. However, the reader is reminded that this list of seven is by no means exhaustive and that virtually any RNA virus may, with appropriate engineering, have potential as an antitumor agent.
Mumps virus
Oncolytic virotherapy was very much in vogue in the 1950s, 1960s, and early 1970s. At that time, numerous viruses were administered by several different routes to hundreds of patients with various treatment-refractory malignancies. 1, 2 In general, the results were tantalizing, but ultimately disappointing. However, the most promising clinical study performed during that era was a study conducted in Japan and reported in 1974 using a tissue culture adapted strain of mumps virus. 3 Mumps virus is a member of the genus Paramyxovirus in the family Paramyxoviridae 4 and was selected for cancer virotherapy trials based on its propensity to flourish in actively multiplying germ cells, causing postpubertal mumps orchitis. As the virus is otherwise of low pathogenicity (mumps is not fatal ) and most adults have antibodies against mumps virus, it was considered reasonable to test its therapeutic potential in human subjects with advanced cancer. A tissue culture suspension of the virus was, therefore, administered to 90 patients with various terminal malignancies, either by local application to the tumor surface, intratumoral inoculation, oral, rectal, or intravenous route, or by inhalation. Toxicity was minimal -limited to occasional febrile reactions, but the clinical responses were most encouraging. In 37 of 90 patients, the tumor disappeared or decreased to less than half of its original size. Minor regressions were observed in an additional of 42 patients. Tumor destruction was maximal several days after the virus was administered, but was often followed by long -term suppression of tumor growth. Antibody titers rose within 1 week after intravenous virus administration or 2 weeks after local injection. The authors, therefore, proposed that the early oncolytic effect was caused by mumps virus multiplication in the tumor, but that spread of the infection was halted by the anamnestic antiviral immune response. The longer-term carcinostatic effect was attributed to stimulation of antitumor immunity. For reasons that are not clear, this extraordinarily encouraging report from Asada et al did not lead to the widespread study of mumps virus as an oncolytic agent in other centers. However, a paper from Shimizu et al 5 in 1988 reported encouraging responses to mumps virus in a group of 22 patients with advanced gynecologic malignancies. In this study, patients were vaccinated subcutaneously with mumps virus to boost their antiviral immunity, and were then treated either locally or systemically with the agent. Interestingly, five of seven patients with ascites or pleural fluid experienced complete disappearance with no recurrence after intracavitary mumps virus administration.
In summary, attenuated mumps remains a highly promising oncolytic virus for the treatment of human malignancy, and further studies utilizing this agent are eagerly anticipated.
Newcastle disease virus
NDV belongs to the Rubulavirus genus of the Paramyxoviridae family. 4 NDV is an economically important avian pathogen causing severe respiratory and central nervous system disease. 6 However, tissue culture -adapted strains of the virus not only show greatly reduced virulence, but also exhibit potent oncolytic activity. NDV strain 73-T has been shown to replicate selectively in human tumor cells, inducing rapid cell -to -cell fusion and tumor cell death. 7 It has been suggested that NDV's tumor cell activity is based on cancerspecific defects in the interferon pathway, 8 but formal proof is lacking for this hypothesis.
The oncolytic potency of NDV strain 73 -T has been very convincingly demonstrated in several human tumor xenograft models. Thus, a single local injection of NDV strain 73-T caused durable, complete regression of human neuroblastoma and fibrosarcoma xenografts grown in athymic mice. 9, 10 Also, in a more recent study, 8 locally administered virus was shown to inhibit the growth of epidermoid, colon, lung, breast, and prostate xenografts. Furthermore, intraperitoneal virus was effective against subcutaneous IMR -32 neuroblastoma xenografts.
Based in part on the aforementioned mouse efficacy studies, a highly purified isolate of the naturally attenuated MK 107 vaccine strain of NDV was tested in a phase I clinical study in patients with advanced solid cancers. 11 The strain of NDV used for this study was named PV 701 and is distinct from the 73 -T strain discussed above. The purpose of the phase I study was to define the maximum tolerated dose (MTD ) and safety of single and multiple intravenous doses of PV 701 as a single agent in patients with cancer. Seventy -nine patients with advanced solid cancer, unresponsive to standard therapy, were enrolled into the study, which established a MTD of 1.2Â10 10 pfu /M 2 for the first dose and a higher MTD of 1.2Â10 11 pfu /M 2 after desensitization by exposure to a lower dose of the virus. Flu -like symptoms were common after the first dose, but less apparent with subsequent doses by which time the patients had developed antiviral immunity. Viable virus was recovered from the urine and, less commonly, sputum of PV 701-treated patients, but did not persist and was cleared within 3 weeks of virus administration. Transient viruria was most commonly observed after the first cycle of treatment and less frequently after subsequent cycles. Two objective responses to PV 701 therapy were documented at the higher dose levels: one complete response in a patient with pharyngeal carcinoma, and one partial response in a patient with drug -resistant colon carcinoma. The overall conclusion of this important clinical study is that PV 701 warrants further study as a novel therapeutic agent for cancer patients.
Measles virus
Measles virus belongs to the family Paramyxoviridae, genus Morbillivirus. 13 Measles remains a serious human pathogen responsible for the deaths of approximately 1 million children each year worldwide. The virus propagates efficiently on EBV-transformed B -cell lines, which may help to explain a dramatic case report in which a large, untreated retro-orbital Burkitt's lymphoma regressed completely during concomitant measles virus infection in an 8-year-old child. 14 However, wild -type measles does not propagate in cell lines derived from human sarcomas or epithelial malignancies. In contrast to wild -type measles, certain members of the Edmonston vaccine lineage are potently and selectively oncolytic against a broad spectrum of lymphoid and nonlymphoid human malignancies. 15 -18 It is well established that the broadened host range of attenuated MV-Edm is a consequence of mutations in the viral attachment glycoprotein that enhance its ability to interact with CD46, a regulator of complement activation that is expressed at high levels on the surface of most human tumors. 19 -21 Thus, tissue culture -adapted strains of MV-Edm have altered receptor specificity, attenuated pathogenicity, and are coincidentally potently and selectively oncolytic. At least in tissue culture, selective tumor cell killing is a consequence of cell -to -cell fusion and subsequent syncytial apoptosis. 22 In contrast to their luxuriant growth on human tumor cells, attenuated MV-Edms propagate poorly on nontransformed human cells, causing minimal cytopathology. However, the basis for this tumor cell activity has yet to be determined. Possibilities under study include defective responsiveness of tumors to measles -generated, double -stranded RNA and the higher density of CD46 expression on tumor cells versus normal tissues.
In vivo, attenuated MV-Edm has been shown to mediate regression of large, established myeloma and lymphoma xenografts after either intratumoral or intravenous administration 15, 17 and of established ovarian tumor xenografts after intraperitoneal administration. 16 However, not all human tumor xenografts were equally responsive to measles virotherapy, a puzzling observation because all of the human tumor cell lines tested were highly susceptible to the virus in the tissue culture dish. To further elucidate the basis for treatment failure in resistant human xenografts ( e.g., failure of virus uptake, rapid virus elimination, or intratumoral virus persistence with no oncolytic effect), MV-Edm was engineered to express a soluble marker peptide whose concentration could be noninvasively monitored in the serum of treated animals. 18 Viruses expressing the soluble extracellular domain of carcinoembryonic antigen (CEA ) or the bchain of human chorionic gonadotrophin were shown to propagate as efficiently as the unmodified MV-Edm from which they were derived, and analysis of the profiles of gene expression in MV-CEA -treated tumor xenografts indicated that resistance to therapy could be due either to failure of virus uptake by the tumor or failure of tumor cell killing in the presence of persistent intratumoral virus infection. Based on its demonstrated potency against an intraperitoneal ovarian tumor xenograft, 16 there are plans to test the MV-CEA virus in a phase I clinical trial.
The measles virus reverse genetic system 11, 23 has been exploited in another way to generate recombinant MV-Edms displaying foreign cell binding polypeptides at the extreme C -terminus of their attachment glycoprotein, the viral hemagglutinin. 24 -26 The conclusion of these studies is that the viral H glycoprotein is surprisingly tolerant to the addition of large cell binding polypeptides, which can efficiently direct virus attachment and entry into otherwise nonpermissive rodent cells. EGF and IGF -1 growth factors, as well as single-chain antibodies against CEA and CD38, were all shown to modulate virus tropism in a receptorspecific fashion. The remaining challenge is to develop retargeted measles viruses in which the natural receptor binding specificity of the H glycoprotein has been fully ablated such that virus attachment and entry are entirely determined by the displayed polypeptide.
Vesicular stomatitis virus
VSV belongs to the genus Vesiculovirus of the family Rabdoviridae, the simplest of the nonsegmented negativestrand RNA viruses. 27 Infection of cattle, horse, and swine is associated with significant but nonfatal disease manifesting as vesicular lesions around the mouth, hooves, and teeth. Human infection is rare and usually asymptomatic.
VSV is exquisitely sensitive to inhibition by interferon 28 such that its propagation is very efficiently inhibited in nontransformed human cells that produce and respond normally to interferon. In contrast, VSV propagates efficiently in many human tumor cell lines leading to cell death, even in the presence of doses of interferon that completely protect normal human primary cell cultures. The differential VSV susceptibility of normal versus transformed cells has been attributed to cancer-specific mutations of gene products in the interferon pathway. 29 However, debate continues as to whether the oncolytic specificity of VSV is entirely attributable to defects in interferon signaling or PKR action. 30 In vivo studies have shown that VSV can inhibit the growth of a human melanoma xenograft in a nude mouse. Also, because of its lack of toxicity when applied to normal bone marrow cultures, the virus has potential as a purging agent for use in autologous bone marrow transplantation. 31 In a later study, VSV was shown to inhibit the growth of a C6 rat glioma xenografted into nude mice when administered by the intravenous route. 30 Intratumoral VSV was also shown to induce regression of Ag 104 sarcomas in immunocompetent C3H mice, thus demonstrating its potential as an oncolytic agent, even in the presence of an intact immune system. 30 Of potential concern with respect to the use of VSV as an oncolytic agent for human studies, it was recently shown that retroviruses expressing the VSVG envelope glycoprotein are efficiently inactivated by human serum. 32 On the basis of its promising but incomplete oncolytic activity discussed above, VSV provides an attractive platform from which to build genetically engineered viruses with enhanced oncolytic activity. Similar to measles virus, the genome of VSV can be expanded by gene insertion without seriously compromising virus replication. Fernandez et al 33 Cancer Gene Therapy RNA viruses as virotherapy agents SJ Russell generated recombinant VSVs able to produce the suicide gene product, thymidine kinase ( TK ), or the cytokine, interleukin -4 ( IL-4). Both the TK -expressing and IL -4 -expressing viruses exhibited considerably more potent oncolytic activity against syngeneic breast and melanoma tumors in immunocompetent mice when compared with the wild -type virus or a control recombinant expressing green fluorescent protein. Furthermore, both IL -4-and TKexpressing viruses showed superior potency when administered intravenously to immunocompetent Balb -C mice bearing mammary adenocarcinomas that were metastatic to lung. This study provides a clear demonstration of the feasibility of oncolytic virus potency enhancement through genetic engineering.
Reovirus
Reovirus is highly prevalent in the human population but not associated with any known human disease and is, therefore, considered to be benign. 34 The virus is nonenveloped and contains 10 segments of double -stranded RNA as its genome. Human reovirus propagates preferentially in tumor cells with an activated RAS pathway, and the molecular basis for this oncolytic specificity has been characterized in some detail. The specificity hinges on the fact that RAS pathway activation induces an endogenous protein inhibitor of PKR activation. 35 Thus, in cells with an activated RAS pathway, the PKR -mediated responses to double -stranded RNA and interferon are defective. Under normal circumstances, early reovirus transcripts trigger PKR phosphorylation, which in turn leads to inhibition of translation of viral genes and control of virus infection. In RAS -transformed cells, this protective pathway is blocked, and virus replication proceeds unchecked. Thus, NIH -3T3 cells are resistant to reovirus infection but become susceptible when transformed with activated RAS. 36 Based on its ability to infect and kill cells with an activated RAS signaling pathway, human reovirus has been tested as an oncolytic agent in several different rodent tumor models. These studies have confirmed that the virus has potent oncolytic activity against human breast, ovarian, colon cancer, and glioma xenografts, and this activity has been demonstrated after intratumoral, intraperitoneal, and intravenous administration of the virus. 37 -40 Most of these mouse tumor therapy studies have been conducted in the absence of a functional immune system using athymic or SCID mice bearing human tumor xenografts. However, efficacy was also demonstrated in immune-competent C3H mice bearing tumors established from syngeneic RAS -transformed fibroblasts. 37 Repeated intratumoral injections of virus were required for efficacy in this study, but the treatment proved to be effective even when the tumor-bearing mice had been preimmunized by intramuscular injection of reovirus 2 weeks before tumor implantation. Based on these encouraging preclinical data, human reovirus is currently being tested in human cancer therapy trials.
In contrast to the other RNA viruses discussed in this paper, there is still no satisfactory reverse genetic system available to facilitate the generation of recombinant reoviruses with modified attachment proteins or carrying additional therapeutic genes. As mentioned previously, the virus genome comprises 10 double -stranded RNA segments and, therefore, presents a significant technical challenge for the development of a reverse genetic system. However, reverse genetic systems have been developed for other double -stranded RNA viruses, 41 and there is every reason to expect that reovirus engineering will become a reality in the near future.
Influenza
Inf luenza virus is a well -known human pathogen belonging to the family Orthomyxoviridae that carries a negative sense, single-stranded RNA genome divided into eight segments. 4 Uniquely among the RNA viruses, orthomyxovirus genomes are transcribed and replicated in the nucleus of the infected cell. In 1904, Dock 42 reported the case of a woman who experienced a dramatic remission of her leukemia following a presumed attack of influenza, and suggested that this observation might teach us something of therapeutic value. However, the virus in Dock's patient was never definitively identified as an influenza virus, and there have been no subsequent reports of influenza virus -mediated tumor regression. Indeed, it would seem that influenza virus lacks the oncolytic specificity that has been demonstrated for the other RNA viruses discussed in this review. However, oncolytic specificity has recently been engineered into the influenza virus genome. 43 The rescue of infectious influenza virus entirely from cloned DNA was first reported by two independent research groups in 1999 ( reviewed in Ref. [44 ] ). This development opened the door for the generation of genetically engineered influenza viruses that might have potential as oncolytic agents. The NS1 protein of influenza virus is a virulence factor that counteracts the PKR -mediated antiviral response by the host. 45 Bergmann et al, 43 therefore, generated a recombinant influenza A virus lacking the NS1 open reading frame, and observed that this virus failed to replicate in normal cells, but produced infectious particles in PKRdeficient cells. As discussed previously, RAS pathway activation, which is common in human malignancy, serves to inhibit PKR, thereby rendering tumor cells susceptible to the NS1 -deleted virus. Direct intratumoral administration of the virus inhibited tumor growth in SCID mice bearing subcutaneous N -RAS expressing melanomas.
Poliovirus
Poliovirus has a single -stranded, positive sense RNA genome and is the best known, most thoroughly characterized, member of the Picornaviridae family. 46 The virus has no intrinsic oncolytic specificity, but it was the first animal RNA virus to be rescued from an infectious DNA clone, and its genome can be readily engineered. 47 In common with other picornaviruses, the poliovirus genome contains an internal ribosome entry site preceding a single, long, open reading frame coding for a large precursor polypeptide that is processed to form about 12 individual viral proteins.
In an attempt to control poliovirus neuropathogenicity, Gromeier et al 48 exchanged the poliovirus IRES with its counterpart from human rhinovirus type II. As expected, this modification led to attenuation of neurovirulence in primates, but in addition, the nonpathogenic polio recombinant retained excellent growth characteristics in cell lines derived from glial neoplasms and was shown to mediate the regression of human glioma xenografts implanted in athymic mice. Intratumoral inoculation of virus was considerably more effective than intravenous administration. Susceptibility of malignant glioma cells to the poliovirus could be correlated with their expression of CD155, the poliovirus receptor.
Conclusion
RNA viruses from several different families are now emerging as powerful antitumor agents with demonstrated oncolytic activity in a variety of murine tumor xenograft models. However, this field of research is at an early stage, and many unanswered questions remain. There is an urgent need for studies that evaluate the oncolytic potential of RNA viruses in the presence of an intact immune system and, perhaps more importantly, in the presence of preexisting antiviral immunity. However, it is possible that immunemediated destruction of virus -infected cells might lead to enhancement of the antitumoral effect. Conversely, neutralization of free virus by circulating antibody and rapid elimination of virus -infected cells may entirely negate the potential therapeutic benefit. In the latter case, immunosuppressive therapy might be deployed to promote prolonged intratumoral spread of the virus. A related issue is the inadequacy of many of the animal models that are currently used to study the therapeutic effects of oncolytic viruses. For example, in the original manuscripts describing the use of VSV and of reovirus for treatment of human tumor xenografts, significant problems were encountered because of lethal virus spread to normal murine tissues. Conversely, CD46, the receptor for oncolytic measles virus, is not expressed in normal mouse tissues, which are therefore completely resistant to virus infection. However, despite the aforementioned problems, this field of research is rapidly gathering momentum, and phase I clinical studies for oncolytic RNA viruses have already begun. At this point in time, the future looks extraordinarily promising.
